Plain-English translation of NCT05099315 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atopic Dermatitis research guide →Researchers want to understand how systemic treatments for severe eczema — including dupilumab, cyclosporine, and baricitinib — affect the bacteria and immune markers in your body. By studying blood samples and skin swabs from people starting these medications, scientists hope to learn why some treatments work better for certain patients and develop even better eczema care in the future.
Severe eczema is complex, and doctors don't yet fully understand how different medications work or why they help some patients more than others. This research could reveal patterns that help doctors choose the best treatment for each person.
You likely qualify if…
You likely don't qualify if…
You'll visit the clinic six weeks after starting your eczema medication, then every three months for two years — following your regular doctor appointments. At each visit, researchers will take a small blood sample to check inflammatory markers and genetics, and gently swab an area of your skin on your upper back to collect bacteria samples. No invasive procedures or pain is involved; these are simple tests done alongside your normal care.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Germany
Charite University, Berlin, Germany
Enrollment target
~600 participants
Started
October 2019
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Margitta Worm, Prof
Charite University, Berlin, Germany
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.